Bespoke Tricyles Inc Common Stock (OB:BPSR)
Business Focus: N/A
Nov 05, 2021 12:43 pm ET
FINRA Approves Marketplace Name Change to Organicell Regenerative Medicine, Inc. and Trading Symbol Change To "OCEL"
MIAMI, Nov. 5, 2021 /PRNewswire/ -- Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that it has received confirmation from the Financial Industry Regulatory Agency ("FINRA") that the pending marketplace name change and trading symbol change request to Organicell Regenerative Medicine, Inc. and "OCEL" has been approved. Accordingly, effective Monday November 8, 2021, the company will have the marketplace name Organicell Regenerative Medicine, Inc. and Organicell common s
Dec 22, 2020 07:30 am ET
Organicell Regenerative Medicine, Inc. Becomes Current with SEC Reporting Requirements
Organicell Regenerative Medicine, Inc. (OTCBB: BPSR) (the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced that it is now current in its SEC reporting requirements under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).
Nov 18, 2020 09:12 am ET
CORRECTING and REPLACING Organicell Announces Additional Site for Phase I/II Clinical Trial of Zofin™ for Treatment of COVID-19
The Phase number of the clinical trial in the first paragraph, first sentence of release should read: Phase I/II (instead of Phase I/I).
Nov 18, 2020 07:00 am ET
Organicell Announces Additional Site for Phase I/II Clinical Trial of Zofin™ for Treatment of COVID-19
Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that it is now enrolling patients at an additional site, Larkin Hospital North located in Hialeah, Florida for its Phase I/I clinical trial for the use of its Zofin™ therapeutic in treatment of COVID-19.
Nov 12, 2020 07:00 am ET
Organicell Provides Update on Its COVID-19 Clinical Trial Using ZofinTM
Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today provided an update on its Phase I/II clinical trial for treatment of COVID-19 using Organicell’s proprietary therapeutic, Zofin™, which is currently underway as well as an update on its expanded access protocol for outpatients with COVID-19.
Oct 20, 2020 07:00 am ET
Organicell Partners with Regenerative Care Network to Study Potential Therapeutic Benefits of Zofin™ for Patients with Heart Failure
Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced that it has recently entered into an agreement with Regenerative Care Network...
Sep 29, 2020 07:00 am ET
FDA Grants Organicell Expanded Access to Treat COVID-19 Patients with Zofin™
Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced that the U.S. Food and Drug Administration (FDA) granted expanded access for an intermediate size population allowing its proprietary therapeutic, Zofin for the treatment of COVID-19.
Sep 02, 2020 07:00 am ET
Three New COVID-19 Patients Treated with Zofin™ Report Improvement
Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced that the U.S. Food and Drug Administration (FDA) granted emergency, expanded access approval to treat two mild to moderate COVID-19 patients and one “Long Hauler” post COVID-19 patient.
Aug 20, 2020 07:00 am ET
First Reported “Long-Hauler” Post COVID-19 Patient Treated with Zofin™ Produces Excellent Preliminary Results
Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced that the U.S. Food and Drug Administration (FDA) granted emergency, expanded access approval to treat one “long-hauler” patient on August 1, 2020, and two additional patient approvals on August 17, 2020.
Aug 18, 2020 07:00 am ET
Organicell Phase I/II Clinical Trial Update
Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that it has partnered with Alternative Research Associates, LLC and Larkin...
Aug 13, 2020 07:00 am ET
Organicell Completes Capital Raise from Retrograde Investments
Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that it has completed an initial capital raise from Retrograde Investments LLC....
Aug 06, 2020 07:00 am ET
FDA Approves Two Emergency INDs for COVID-19 Outpatient Therapy
Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that the U.S. Food and Drug Administration (FDA) approved two outpatient...
May 27, 2020 07:00 am ET
Organicell Reports Positive Results from Compassionate Use of Organicell Flow in Severely Ill COVID-19 Patients
Organicell Regenerative Medicine, Inc. (OTCBB:BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today a health update for two critically ill COVID-19 patients who were treated at...
May 19, 2020 07:00 am ET
FDA Approves Two Emergency INDs to Administer Organicell Flow for COVID-19
Organicell Regenerative Medicine, Inc. (OTCBB:BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that on May 11, 2020, the U.S. Food and Drug Administration (FDA) authorized two...
May 05, 2020 08:00 am ET
Organicell Announces FDA Approval of IND Application for the Treatment of SARS Due to COVID-19
Organicell Regenerative Medicine, Inc. (OTCBB:BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that the U.S. Food and Drug Administration (FDA) has approved the...
Jan 21, 2020 09:54 am ET
Organicell Regenerative Medicine Inc. Provides Update On Operations and Financial Reporting Status
Organicell Regenerative Medicine Inc. (OTCPK:BPSR) (the “Company”) is pleased to provide shareholders and the investment community with an update on operations since its filing on November 1, 2018 of the Company’s Annual Report on Form filing of...
Feb 25, 2019 12:00 pm ET
Organicell Welcomes Dr. George C. Shapiro To The Medical Advisory Board
BOCA RATON, Fla., Feb. 25, 2019 /PRNewswire/ -- Biotech Products Services and Research, Inc. operating as Organicell Regenerative Medicine Inc. (OTC: BPSR), today announced the appointment of George C. Shapiro, M.D. F.A.C.C. to its medical advisory board. In addition to serving on the Company's Advisory Board, Dr. Shapiro is assembling the medical advisory board for Organicell.
Jan 30, 2019 12:35 pm ET
Organicell Regenerative Medicine Inc., Biotech Products Services and Research, Inc. Update for Shareholders
BOCA RATON, Fla., Jan. 30, 2019 /PRNewswire/ -- Biotech Products Services and Research, Inc. operating as Organicell Regenerative Medicine Inc. (OTC: BPSR), today is providing its shareholders with an update on the Company's progress.
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.